393105-53-8 | Tiplaxtinin

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$15.00	$10.00
5mg	99%	in stock	$18.00	$12.00
10mg	99%	in stock	$22.00	$15.00
25mg	99%	in stock	$40.00	$28.00
50mg	99%	in stock	$66.00	$46.00

Description

• Catalog Number: AB51104
• Chemical Name: Tiplaxtinin
• CAS Number: 393105-53-8
• Molecular Formula: C24H16F3NO4
• Molecular Weight: 439.3833
• MDL Number: MFCD09475615
• SMILES: OC(=O)C(=O)c1cn(c2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ccccc1

Computed Properties

• Complexity: 671
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 5.8

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity.

  Glia 20130501

• Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives.

  Bioorganic & medicinal chemistry letters 20111001

• Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice.

  Diabetes 20110701

• Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?

  International journal of molecular medicine 20100701

• In vitro PAI-1 inhibitory activity of oxalamide derivatives.

  European journal of medicinal chemistry 20080401

• Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.

  Thrombosis and haemostasis 20080401

• S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.

  Thrombosis research 20080101

• Tiplaxtinin impairs nutritionally induced obesity in mice.

  Thrombosis and haemostasis 20061201

• Modulation of adipose tissue development by pharmacological inhibition of PAI-1.

  Arteriosclerosis, thrombosis, and vascular biology 20061001

• Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1.

  Bioorganic & medicinal chemistry letters 20050801

• On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.

  Journal of thrombosis and haemostasis : JTH 20050601

• Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

  Journal of medicinal chemistry 20040701